About PhaseRx
PhaseRx is a company based in Seattle (United States) founded in 2006 by Paul H Johnson. PhaseRx has raised $32.82 million across 9 funding rounds from investors including Arch Venture Partners, 5AM Ventures and Versant Ventures. The company has 21 employees. PhaseRx operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Strand Therapeutics, among others.
- Headquarter Seattle, United States
- Employees 21
- Founders Paul H Johnson
- Stage Public
- SectorsHealthcare
- Website phaserx.com
- Social LinkedIn
- Legal Name Phaserx, Inc.
- Total Equity Funding$32.82M (USD)
in 9 rounds
- Latest Funding Round$6M (USD), Debt – Venture
Jun 2016
- InvestorsArch Venture Partners
& 2 more
- Employee Count21
Funding Insights of PhaseRx
PhaseRx has successfully raised a total of $32.82M across 9 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $6 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.82M
- Total Rounds 9
- Last Round Debt – Venture — $6M
- First Round $19M
(Feb 2008)
- Investors Count 3
All 9 funding rounds of PhaseRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $6M | Debt – Venture | – | – | – |
| Dec 2015 | $4M | Series A | – | – | – |
| Oct 2013 | $1.4M | Series A | – | – | – |
| Jul 2013 | $500,005 | Series A | – | – | – |
| Dec 2012 | $1.5M | Series A | – | – | – |
| Jul 2012 | $1.6M | Series A | – | – | – |
| Feb 2012 | $3.6M | Series A | – | – | – |
| Feb 2010 | $1.22M | Series A | – | – | – |
| Feb 2008 | $19M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in PhaseRx
PhaseRx has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Arch Venture Partners, 5AM Ventures and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital fund backed incubator focused on the healthcare startups | – | 5amventures.com | San Francisco, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - |
Investor details for PhaseRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PhaseRx
1 people are tracked at PhaseRx (1 in leadership); the tracked headcount is 21.
| Name | Role | Group |
|---|---|---|
Paul H Johnson | Founder | Leadership |
Complete people profiles for PhaseRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PhaseRx
4 dated milestones of PhaseRx across 10 years, from founding to its latest funding, stage changes and deals.
- Founded PhaseRx is founded.
- Funding First funding round of $19.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Venture, of $6.0M.
Competitors of PhaseRx
PhaseRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Strand Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| amicusrx.com | 2002 | Philadelphia, United States | $91M | 517 | Developer of therapies for rare and orphan diseases | |
| audentestx.com | 2013 | San Francisco, United States | $137.5M | 404 | Developer of therapeutics to treat rare genetic diseases | |
| fulcrumtx.com | 2015 | Cambridge, United States | $114.67M | 104 | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | |
| generationbio.com | 2016 | Cambridge, United States | $236.47M | 155 | Gene therapies for rare liver and eye diseases are developed. |
Detailed competitors of PhaseRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PhaseRx
Websites that share an audience with PhaseRx (phaserx.com).
Websites whose visitors overlap most with PhaseRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sirnaomics.com | 100% | 1.9K | #8,322,653 | View details | |
genscript.jp | genscript.jp | 99% | – | #1,512,314 | – |
marinabio.com | marinabio.com | 99% | – | – | – |
Latest news on Phaserx
Complete news archive for PhaseRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PhaseRx
10 companies that operate in the same segment as PhaseRx (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PhaseRx
PhaseRx was founded in 2006 and raised its 1st funding round 2 years after it was founded.
PhaseRx is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
PhaseRx is a funded company, having raised a total of $32.82M across 9 funding rounds to date. The company's 1st funding round was a Series A of $19M, raised on Feb 2008.
PhaseRx has 21 employees.
PhaseRx was founded in 2006 in Seattle, United States, within the biotechnology sector. Treatments for orphan liver diseases and inherited metabolic conditions are developed using a proprietary Hybrid mRNA Delivery System. This system enables targeted delivery of messenger RNA to specific tissues in vivo. Clinical candidates are advanced for these therapeutic areas, focusing on RNA-based interventions.
PhaseRx's top competitors include Moderna, Spark Therapeutics and BridgeBio.
PhaseRx has 3 investors. Key investors include Arch Venture Partners, 5AM Ventures, and Versant Ventures.
PhaseRx operates through Phaserx, Inc..